These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

382 related articles for article (PubMed ID: 22003224)

  • 1. Morphine-induced epidermal growth factor pathway activation in non-small cell lung cancer.
    Fujioka N; Nguyen J; Chen C; Li Y; Pasrija T; Niehans G; Johnson KN; Gupta V; Kratzke RA; Gupta K
    Anesth Analg; 2011 Dec; 113(6):1353-64. PubMed ID: 22003224
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Inhibition of EGF-induced ERK/MAP kinase-mediated astrocyte proliferation by mu opioids: integration of G protein and beta-arrestin 2-dependent pathways.
    Miyatake M; Rubinstein TJ; McLennan GP; Belcheva MM; Coscia CJ
    J Neurochem; 2009 Jul; 110(2):662-74. PubMed ID: 19457093
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The fibroblast growth factor receptor is at the site of convergence between mu-opioid receptor and growth factor signaling pathways in rat C6 glioma cells.
    Belcheva MM; Haas PD; Tan Y; Heaton VM; Coscia CJ
    J Pharmacol Exp Ther; 2002 Dec; 303(3):909-18. PubMed ID: 12438509
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Insights into erlotinib action in pancreatic cancer cells using a combined experimental and mathematical approach.
    Lange F; Rateitschak K; Kossow C; Wolkenhauer O; Jaster R
    World J Gastroenterol; 2012 Nov; 18(43):6226-34. PubMed ID: 23180942
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Gastrin-releasing peptide receptor mediates activation of the epidermal growth factor receptor in lung cancer cells.
    Thomas SM; Grandis JR; Wentzel AL; Gooding WE; Lui VW; Siegfried JM
    Neoplasia; 2005 Apr; 7(4):426-31. PubMed ID: 15967120
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The Mu opioid receptor promotes opioid and growth factor-induced proliferation, migration and Epithelial Mesenchymal Transition (EMT) in human lung cancer.
    Lennon FE; Mirzapoiazova T; Mambetsariev B; Poroyko VA; Salgia R; Moss J; Singleton PA
    PLoS One; 2014; 9(3):e91577. PubMed ID: 24662916
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Kinase switching in mesenchymal-like non-small cell lung cancer lines contributes to EGFR inhibitor resistance through pathway redundancy.
    Thomson S; Petti F; Sujka-Kwok I; Epstein D; Haley JD
    Clin Exp Metastasis; 2008; 25(8):843-54. PubMed ID: 18696232
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Sensitivity to gefitinib (Iressa, ZD1839) in non-small cell lung cancer cell lines correlates with dependence on the epidermal growth factor (EGF) receptor/extracellular signal-regulated kinase 1/2 and EGF receptor/Akt pathway for proliferation.
    Ono M; Hirata A; Kometani T; Miyagawa M; Ueda S; Kinoshita H; Fujii T; Kuwano M
    Mol Cancer Ther; 2004 Apr; 3(4):465-72. PubMed ID: 15078990
    [TBL] [Abstract][Full Text] [Related]  

  • 9. RAF1-MEK1-ERK/AKT axis may confer NSCLC cell lines resistance to erlotinib.
    Xu ZH; Hang JB; Hu JA; Gao BL
    Int J Clin Exp Pathol; 2013; 6(8):1493-504. PubMed ID: 23923067
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mu opioid transactivation and down-regulation of the epidermal growth factor receptor in astrocytes: implications for mitogen-activated protein kinase signaling.
    Belcheva MM; Tan Y; Heaton VM; Clark AL; Coscia CJ
    Mol Pharmacol; 2003 Dec; 64(6):1391-401. PubMed ID: 14645669
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Molecular mechanism of erlotinib resistance in epidermal growth factor receptor mutant non-small cell lung cancer cell line H1650].
    Han R; Wang X; Zhong D; Zhao J; Chen Z; Sun L; Wang J; Zhang J
    Zhongguo Fei Ai Za Zhi; 2012 Dec; 15(12):689-93. PubMed ID: 23249714
    [TBL] [Abstract][Full Text] [Related]  

  • 12. mu-Opioid receptor-mediated ERK activation involves calmodulin-dependent epidermal growth factor receptor transactivation.
    Belcheva MM; Szùcs M; Wang D; Sadee W; Coscia CJ
    J Biol Chem; 2001 Sep; 276(36):33847-53. PubMed ID: 11457825
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Laser capture microdissection and protein microarray analysis of human non-small cell lung cancer: differential epidermal growth factor receptor (EGPR) phosphorylation events associated with mutated EGFR compared with wild type.
    VanMeter AJ; Rodriguez AS; Bowman ED; Jen J; Harris CC; Deng J; Calvert VS; Silvestri A; Fredolini C; Chandhoke V; Petricoin EF; Liotta LA; Espina V
    Mol Cell Proteomics; 2008 Oct; 7(10):1902-24. PubMed ID: 18687633
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Morphine promotes tumorigenesis and cetuximab resistance via EGFR signaling activation in human colorectal cancer.
    Lu H; Zhang H; Weng ML; Zhang J; Jiang N; Cata JP; Ma D; Chen WK; Miao CH
    J Cell Physiol; 2021 Jun; 236(6):4445-4454. PubMed ID: 33184860
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Morphine Prevents Ischemia/Reperfusion-Induced Myocardial Mitochondrial Damage by Activating δ-opioid Receptor/EGFR/ROS Pathway.
    Xu J; Bian X; Zhao H; Sun Y; Tian Y; Li X; Tian W
    Cardiovasc Drugs Ther; 2022 Oct; 36(5):841-857. PubMed ID: 34279751
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Molecular mechanisms underlying the synergistic interaction of erlotinib, an epidermal growth factor receptor tyrosine kinase inhibitor, with the multitargeted antifolate pemetrexed in non-small-cell lung cancer cells.
    Giovannetti E; Lemos C; Tekle C; Smid K; Nannizzi S; Rodriguez JA; Ricciardi S; Danesi R; Giaccone G; Peters GJ
    Mol Pharmacol; 2008 Apr; 73(4):1290-300. PubMed ID: 18187583
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Increased 6-phosphofructo-2-kinase/fructose-2,6-bisphosphatase-3 activity in response to EGFR signaling contributes to non-small cell lung cancer cell survival.
    Lypova N; Telang S; Chesney J; Imbert-Fernandez Y
    J Biol Chem; 2019 Jul; 294(27):10530-10543. PubMed ID: 31126985
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Arsenic activates EGFR pathway signaling in the lung.
    Andrew AS; Mason RA; Memoli V; Duell EJ
    Toxicol Sci; 2009 Jun; 109(2):350-7. PubMed ID: 19168569
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Impaired SHP2-mediated extracellular signal-regulated kinase activation contributes to gefitinib sensitivity of lung cancer cells with epidermal growth factor receptor-activating mutations.
    Lazzara MJ; Lane K; Chan R; Jasper PJ; Yaffe MB; Sorger PK; Jacks T; Neel BG; Lauffenburger DA
    Cancer Res; 2010 May; 70(9):3843-50. PubMed ID: 20406974
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Elevated expression of Fn14 in non-small cell lung cancer correlates with activated EGFR and promotes tumor cell migration and invasion.
    Whitsett TG; Cheng E; Inge L; Asrani K; Jameson NM; Hostetter G; Weiss GJ; Kingsley CB; Loftus JC; Bremner R; Tran NL; Winkles JA
    Am J Pathol; 2012 Jul; 181(1):111-20. PubMed ID: 22634180
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.